To improve targeted therapy, breast cancer is clinically divided into three main subtypes according to immunohistochemical markers: estrogen receptor-positive breast cancer, triple-negative breast cancer, and human epidermal growth factor receptor 2 (HER-2)-positive breast cancer. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.